| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.7M | — | +21.6% |
| R&D Expense | $30.7M | — | +188.8% |
| SG&A Expense | $25.1M | — | +49.9% |
| Operating Income | -$43.1M | — | -154.9% |
| Income Tax | $0 | — | — |
| Net Income | -$41.4M | — | -154.2% |
| EPS (Basic) | -$0.13 | — | +7.1% |
| EPS (Diluted) | -$0.13 | — | +7.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $184.2M | -18.8% | +283.0% |
| Accounts Receivable | $11.6M | -16.3% | +36.1% |
| Current Assets | $204.9M | -17.2% | +170.2% |
| Total Assets | $241.7M | -12.7% | +133.0% |
| Current Liabilities | $31.7M | -7.3% | -36.2% |
| Total Liabilities | $38.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$41.7M | — | -97.4% |
| Capital Expenditures | $726K | — | +404.2% |
| Investing Cash Flow | -$726K | — | -404.2% |
| Financing Cash Flow | -$98K | — | -1080.0% |
| Free Cash Flow | -$42.4M | — | -99.5% |
| -22.0% |
| Stockholders' Equity | $203.1M | -15.9% | +275.0% |